节点文献

5-HT1A受体参与常见精神疾病病理机制及5-HT1A受体部分激动剂的潜在治疗效应研究进展

Advance on role of 5-HT1A receptor in psychopathology of mental disorders and potential therapeutic effects of 5-HT1A receptor partial agonist

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 司天梅陈胜良郝伟王毅王少石

【Author】 SI Tian-mei;CHEN Sheng-liang;HAO Wei;WANG Yi;WANG Shao-shi;National Clinical Research Center for Mental Disorders, Peking University Sixth Hospital & Key Laboratory of Mental Health, Ministry of Health, Peking University;Renji Hospital,Shanghai Jiaotong University School of Medicine;Mental Health Institute, the Second Xiangya Hospital of Center South University;Huashan Hospital, Fudan University;Branch of Shanghai General Hospital;

【机构】 国家精神心理疾病临床医学研究中心北京大学第六医院&卫生部精神卫生学重点实验室北京大学上海交通大学医学院附属仁济医院中南大学湘雅二医院精神卫生研究所复旦大学附属华山医院上海市第一人民医院分院

【摘要】 5-羟色胺(5-HT)是脑内重要的神经递质,参与神经可塑性调节。5-HT突触间隙、神经元内5-HT水平和5-HT受体功能等变化,均可能改变脑内神经发育过程,导致各种精神疾病发生。5-HT有多种受体亚型,其中5-HT1A受体是最重要的一类受体,作为5-HT的负反馈调节受体,分布于突触前膜或胞体,调节5-HT神经元的兴奋性(放电活动)和突触前膜5-HT的释放;作为突触后膜受体,分布于锥体神经元和中间神经元等,调节神经可塑性,在焦虑障碍、抑郁症、创伤后应激障碍和精神分裂症等常见精神疾病病理机制中起着重要作用。本文系统回顾5-HT1A受体参与上述精神疾病的病理机制研究,提示5-HT1A受体部分激动剂的潜在治疗价值。

【Abstract】 Serotonin( 5-HT) is a neurotransmitter that plays an important role in neuronal plasticity.Variations in the levels of 5-HT in the synaptic cleft or neurons and the dysfunction of 5-HT receptors may alter brain development and predispose to various mental diseases. Given the diversity of 5-HT receptors, 5-HT1A receptor( 5-HT1AR) is the most important receptor, both an autoreceptor of 5-HT expressed in presynaptic membrane and cell bodies to modulate the firing of cell and release of 5-HT, and a postsynaptic receptor expressed in pyramidal neurons and interneurons to modulate the neuronal plasticity, involved in the psychopathology of anxiety, depression, post-traumatic stress disorder and schizophrenia. This paper reviewed the involvement of 5-HT1AR in the pathogenesis of these mental disorders suggesting the potential therapeutic value of 5-HT1AR partial agonists in treating anxiety, depression and schizophrenia.

  • 【文献出处】 中国新药与临床杂志 ,Chinese Journal of New Drugs and Clinical Remedies , 编辑部邮箱 ,2018年09期
  • 【分类号】R749
  • 【被引频次】18
  • 【下载频次】856
节点文献中: 

本文链接的文献网络图示:

本文的引文网络